Compare Apollo Global Management Ord Shs (APO) vs Eli Lilly And Co (LLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Apollo Global Management Ord Shs vs Eli Lilly And Co — how do they compare? Apollo Global Management Ord Shs trades at $120.68 (market cap $69.38B), while Eli Lilly And Co trades at $1,188.63 (market cap $1.06T). The key difference: Eli Lilly And Co is far larger — about 15.3× Apollo Global Management Ord Shs's market cap, and Apollo Global Management Ord Shs pays the higher dividend (1.87%). Which is the better fit depends on your goals.
| APO | LLY | |
|---|---|---|
Market Cap | $69.38B | $1.06T |
Sector | Financials | Health |
52-Week High | $156.05 | $1.24K |
52-Week Low | $100.30 | $625.65 |
Enterprise Value | -$168.19B | $1.10T |
Dividend Yield | 1.87% | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Apollo Global Management (APO) trades at $120.34, up 0.42% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported Q1 2026 EPS of $1.94, beating estimates, and maintains strong analyst support with 23 buy ratings. Recent news highlights private credit growth opportunities alongside liquidity concerns in Apollo's funds.
APO's outlook is supported by earnings beats and a $149.86 consensus price target, but risks include private credit liquidity pressures and a high P/E ratio of 75.69. Investor sentiment is mixed due to ongoing fund withdrawal caps and legal investigations, though long-term growth in alternative assets remains a positive catalyst.
Eli Lilly (LLY) trades at $1,188.58, down 2.33% over 24 hours, but maintains a strong technical bullish trend with support near $1,172. The company demonstrates exceptional fundamental strength, with 2025 revenue surging to $65.18B and net income reaching $20.64B, driven by robust demand for its obesity and diabetes drugs. Recent news highlights a $400B market cap surge over the past year and positive analyst coverage, though valuation multiples remain elevated.
Outlook remains positive given Lilly's dominance in high-growth therapeutic areas and consistent earnings beats, but risks include intense competition from Novo Nordisk and rich valuations. Wall Street consensus is strongly bullish with a $1,340 price target, suggesting 13% upside from current levels, supported by institutional confidence in long-term growth prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Apollo Global Management Ord Shs
Apollo Global Management Inc is an alternative investment manager. It serves various sectors such as chemicals, manufacturing and industrial, natural resources, consumer and retail, consumer services, business services, financial services, leisure, and media and telecom and technology. The company operates in three business segments that are Private Equity, Credit, and Real Assets. It generates maximum revenue from the Credit segment in the form of fees. The credit segment primarily invests in non-control corporate and structured debt instruments including performing, stressed and distressed instruments across the capital structure. It also includes Corporate Credit
Read more on APO →About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →
